Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13749900 | 0.89 | SMN1; SMN2 (0.54) | SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL13749488 | 0.86 | TSHR (0.51) | SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL13749871 | 0.84 | TSHR (0.44) | SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL13749626 | 0.83 | TSHR (0.50) | SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL13749862 | 0.81 | SMN1; SMN2 (0.44) | SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL13749636 | 0.80 | HDAC6 (0.48) | SMN1; SMN2L3MBTL1TSHRALDH1A1 | |
| SCHEMBL13749517 | 0.80 | SMN1; SMN2 (0.45) | SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL13749896 | 0.79 | PDF (0.52) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL13750039 | 0.79 | TSHR (0.48) | SMN1; SMN2L3MBTL1TSHR | |
| SCHEMBL13749485 | 0.79 | SMN1; SMN2 (0.44) | SMN1; SMN2L3MBTL1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579363-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2009-08-25 | — | — | US | disclosed |
| US-7579363-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2009-08-25 | — | — | US | disclosed |
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC | 2007-11-08 | — | — | US | disclosed |
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | IRM LLC | 2007-11-08 | — | — | US | disclosed |
| US-7253164-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2007-08-07 | — | — | US | disclosed |
| US-7253164-B2 | Bicyclic compounds and compositions as PDF inhibitors | IRM LLC (BM) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259852-A1 | BICYCLIC COMPOUNDS AND COMPOSITIONS AS PDF INHIBITORS | PDF, FDPS, DCTPP1 | SMN1; SMN2 2458/4885L3MBTL1 2695/4885TSHR 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.